Communiqués Castle Biosciences, Inc.

Actions

CSTL

US14843C1053

Equipement, fournitures et distribution médicale

Temps réel estimé Cboe BZX Autres places de cotation 20:07:34 06/08/2026			Varia. 5j.	Varia. 1 janv.
29,98 ^USD	-1,40%		+11,59%	-23,15%

31/07	Transcript : Castle Biosciences, Inc., Q2 2026 Earnings Call, Jul 30, 2026
30/07	Flash résultats (CSTL) : Castle Biosciences publie un chiffre d'affaires de 103,5 millions de dollars au deuxième trimestre, contre 86,2 millions de dollars attendus par le consensus FactSet	MT

Communiqués

23/07	Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference	AQ
15/07	Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx Test	AQ
09/07	Castle Biosciences : to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026	PU
25/06	Castle Biosciences : DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy	PU
07/05	Castle Biosciences : Reports First Quarter 2026 Results	PU
05/05	Castle Biosciences Supports Nationwide Patient Advocacy and Screening Initiatives to Celebrate Skin Cancer Awareness Month	PR
04/05	New Data at DDW 2026 Show TissueCypher® Testing Improves Risk Stratification and Drives Risk-Aligned Management in Barrett's Esophagus	PR
30/03	Castle Biosciences' DecisionDx(R)-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026	AQ
27/03	Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026	PR
13/03	Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’s i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB	GL
09/03	DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk	GL
04/03	Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB	GL
03/03	Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas	GL
26/02	Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results	GL
19/02	Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis	GL
05/02	Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026	GL
11/01	Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results	GL
19/12	Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
18/12	Landmark Study Shows Combination of Castle Biosciences DecisionDx-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma	AQ
17/12	Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma	GL
12/12	Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer	AQ
12/12	Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer	GL
10/12	Expert Melanoma Panel Recommends Castle Biosciences DecisionDx-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma	AQ
09/12	Expert Melanoma Panel Recommends Castle Biosciences’ DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma	GL
17/11	Castle Biosciences, Inc. - New Data Confirms Performance of DecisionDx-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity	AQ